The present study found that MK2206 did not completely reverse effects associated with MTA1 expression changes, indicating that pathways besides AKT/GSK3β/β-catenin signaling could be involved in MTA1-induceed EMT in NSCLC. The gene discussed is MTA1; the disease is non-small cell lung carcinoma.